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Abstract
Burkitt's lymphoma (BL) is a heterogeneous group of highly aggressive mature B-cell malignancies.
It is characterized by a high rate of turnover of malignant cells and deregulation of the c-myc gene.
It is typically associated with a t(8;14) translocation. Dual translocation of t(8;14) (c-myc) and
t(14;18) (bcl-2) was reported to be associated with extremely poor prognosis. This study reports
a novel t(8;14;18) triple translocation in two patients with Burkitt's lymphoma.
Background
Burkitt's lymphoma/leukemia (BL) is a heterogeneous
group of highly aggressive mature B-cell malignancies. It
is characterized by a high rate of turnover of malignant
cells and deregulation of the c-myc gene. The BL tumor
cells usually express the B-cell-specific surface markers
CD19, CD20, together with surface immunoglobulin (Ig),
as well as CD10. The histologic hallmark of BL is the pres-
ence of apoptotic cells within scattered macrophages, a
feature responsible for the "starry sky" microscopic
appearance. A characteristic chromosome translocation
associated with this disease typically takes place between
chromosome 8q24 (c-myc) and one of the Ig gene-con-
taining chromosomes, 14q32 (Ig H gene), 2p12 (Ig kappa)
or 22q11 (Ig lambda). The frequency of such translocation
is estimated to be approximately 80% t(8;14), 15% t(2;8),
and 5% t(8;22), respectively [1]. We report in this study




A 61 year- old Arabic female presented with abdominal
pain, weakness and fever in April, 1997. Physical exami-
nation was significant for splenomegaly. Her laboratory
revealed WBC 2.7 × 109/L, Hgb 107 g/L, platelets 178 ×
109/L, and LDH 1250 u/L. CT scan confirmed splenome-
galy. Bone marrow was hypercellular with 30% lymphoid
blasts. Flowcytometric analysis revealed a B cell popula-
tion expressing CD19, CD20, CD22, HLA-DR and kappa,
but negative for CD5, CD10, CD23, and CD34, and tdT.
The chromosome analysis of the bone marrow revealed
47, XX, +7, t(8;14;18) (q24;q32;q22) (Fig. 1). This was
consistent with BL by WHO criteria. She was given chem-
otherapy with cyclophosphamide, doxorubicin, vincris-
tine, and prednisone following the L-20 regimen [2,3].
The patient was in complete remission (CR) and received
maintenance chemotherapy. In November, 2002 she felt
abdominal pain without any other complaint. Physical
Published: 4 June 2007
Molecular Cancer 2007, 6:35 doi:10.1186/1476-4598-6-35
Received: 28 February 2007
Accepted: 4 June 2007
This article is available from: http://www.molecular-cancer.com/content/6/1/35
© 2007 Liu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2007, 6:35 http://www.molecular-cancer.com/content/6/1/35
Page 2 of 5
(page number not for citation purposes)
examination was unremarkable. WBC 4.7 × 109/L, Hgb
115 g/L, and platelets 215 × 109/L. CT scan revealed
marked intra-abdominal lymphadenopathy. Bone mar-
row smear and flowcytometric analysis did not show overt
involvement by BL, though focal involvement of the bone
marrow was demonstrated on immunohistochemical
study. The cytogenetic analysis from the bone marrow
sample revealed only 46 XX. She was given the intensive
chemotherapy with rituxamab plus hyper-CVAD [4]. She
also received radiation therapy to the residual mass. She
subsequently completed two years of maintenance ther-
apy in August 2005 and has remained in CR at the time of
this report.
Case 2
A 56 year- old Hispanic male went to ER with worsening
left sided facial pain with erythema and edema. Physical
examination was significant for lymphadenopathy in the
neck and inguinal areas as well as splenomegaly. He also
had decreased air entry in both lungs and bilateral ankle
edema. His CBC revealed WBC 28.4 × 109/L, Hgb 109 g/
L, and platelets 330 × 109/L. The chemistry panel was sig-
nificant for BUN 58 mg/dL, Creatinine 4.7 mg/dL, LDH >
2500 u/L, Uric acid 27.8 mg/dL. CT scan revealed bilateral
pleural effusions, splenomegaly, massive matted retro-
peritoneal lymphadenopathy and bilateral inguinal lym-
phadenopathy. MRI of the brain showed a 5 cm left
pterygoid muscle mass extending into the cavernous sinus
and lateral aspect of the orbit. Bone marrow was hypercel-
lular and partially replaced by intermediate to large-sized
neoplastic lymphoid cells with cytoplasmic vacuoles.
Flowcytometric analysis revealed a B cell population
expressing CD19, CD20, CD22, CD10(dim), surface IgG,
HLA-DR and CD43, but negative for CD5, CD34, and tdT.
The chromosome analysis of the bone marrow revealed
44–49, XY, t(3;5) (q27;q15), t(8;14;18) (q24;q32;q21),
+der (8) t(8;14;18), +der(18) t(8;14;18) (Fig. 2). FISH
study was positive for gene rearrangement of bcl-6, and
fusions of myc, IgH, and bcl-2 (Fig. 2). This was consistent
with BL. He received hemodialysis for his acute renal fail-
ure. He was given the intensive chemotherapy with ritux-
imab plus hyper- CVAD. His lymphadenopathy resolved
on examination. His renal function returned to normal
quickly, and his blood counts returned to normal range
upon discharge from the hospital.
This study identified two cases of BL with this novel
t(8;14;18) triple translocation from one institution over
10 years. The first patient relapsed five and a half years
after initial diagnosis, but her disease remained to be
Cytogenetic abnormalities in case 1 Figure 1
Cytogenetic abnormalities in case 1. (A). Karyotype 47, XX, +7, t(8;14;18) (q24.1;q32;q22). Arrows indicate abnormal chromo-
somes. (B). Diagramatic representation of +7 and 3-way chromosome translocations. Arrows indicated abnormal chromosome 
regions involved in the 3-way translocation.
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chemo-sensitive. Gene locus translocations of myc, IgH,
and bcl-2 were confirmed by FISH analysis in the second
case. After extensive literature search and review, we
believe this is the first report of t(8;14;18) triple transloca-
tion associated with clinical cases (Table 1). A review of a
large cytogenetic database from 1350 leukemia and lym-
phoma karyotypes disclosed eight cases with karyotypes
of t(8;14) and t(14;18) involving 3-way recombinations
of MYC-IGH-BCL2 [5]. Interestingly, 3-way recombina-
tions of MYC-IGH-BCL2 were demonstrated by multi-
color FISH and locus-specific FISH analysis [5]. It is
therefore possible that the 3-way recombinations of MYC-
IGH-BCL2 may take place more often than it is reported,
since the multicolor FISH and locus-specific FISH are not
Cytogenetic abnormalities in case 2 Figure 2
Cytogenetic abnormalities in case 2. (A). Karyotype 44–49, XY, t(3;5) (q27;q15), t(8;14;18) (q24;q32;q21), +der (8) t(8;14;18), 
+der(18) t(8;14;18). Arrows indicate abnormal chromosomes. (B) IgH/myc gene fusion. (C). IgH/bcl-2 gene fusion. (D). bcl-6 
gene rearrangement.
A. Karyotype B. IgH/myc
C. IgH/bcl-2 D. bcl-6
Table 1: 3-way translocations associated with Burkitt's lymphoma/leukemia
Author Karyotype *Genes Source Reference
Ooteghem, 1994 t(8;14;18) bcl-2 cell line 6
Dyer,1996 t(8;14;18) NR cell line 7
Zimonjic, 2001 t(8;14;18) NR cell line 8
t(7;8;14) NR cell line 8
Zani,1996 t(8;14;12) bcl-7a cell line 13
Macpherson, t(1;8;22) NR patient 9
1999 t(1;14;18) NR patient 9
t(12;14;18) NR patient 9
Liu, 2007 t(8;14;18) NR patient TR
t(8;14;18) bcl-2 patient TR
*genes: gene mutation in addition to c-myc. NR: not reported. TR: this reportMolecular Cancer 2007, 6:35 http://www.molecular-cancer.com/content/6/1/35
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routinely done. It appears nonetheless that this 3-way
chromosome translocation is an extremely rare genetic
event occurring in clinical cases. There have been three
separate reports of t(8;14;18) 3-way translocation that
were found in BL cell lines [6-8]. Dual translocations of
t(8;14) and t(14;18) involving c-myc and bcl-2 have been
reported in Burkitt-like lymphoma patients [9-12]. 13
such patients with the dual translocation were found to
have rapid clinical course and extremely poor prognosis
[9]. None of the 13 patients survived past 7 months. Three
cases of non-Burkitt lymphoma in the same report had tri-
ple translocations of t(1;8;22), t(1;14;18), and
t(12;14;18), respectively [9]. t(7;8;14) was found in BL
cell line, CA46 [8]. In another cell line of BL, a novel gene,
bcl7a, from the triple translocation t(8;14;12) was identi-
fied [13]. c-myc translocation can also be seen in diffuse
large B-cell lymphoma (DLBCL). DLBCL with c-myc
translocation can be difficult to reliably differentiate from
BL by currently available diagnostic tools [14]. Through
gene expression profiling, eight cases of pathologically-
diagnosed DLBCL and one case of high-grade lymphoma
were reclassified as BL. These nine cases all expressed c-
myc, bcl-2, and had high Ki-67 scores [14]. It is crucial to
distinguish between DLBCL and BL, since the overall sur-
vival of those BL patients who were treated with intensive
regimens were superior to those who received CHOP-like
regimens [14]. Regardless of pathological diagnosis of BL
or Burkitt-like lymphoma, it seems that poor-prognostic
patients with dual and triple translocations involving c-
myc and bcl-2 should receive intensive chemotherapy
[2,3]. It is unclear whether hematopoietic stem cell trans-
plantation plays any role in the therapy of BL with com-
plex chromosome translocations [15-18].
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